GeoVax Labs - GOVX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.67
  • Forecasted Upside: 511.92%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 2 Strong Buy Ratings
$2.07
▼ -0.03 (-1.43%)

This chart shows the closing price for GOVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GeoVax Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GOVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GOVX

Analyst Price Target is $12.67
▲ +511.92% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for GeoVax Labs in the last 3 months. The average price target is $12.67, with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a 511.92% upside from the last price of $2.07.

This chart shows the closing price for GOVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in GeoVax Labs. This rating has held steady since August 2024, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/14/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2024

Latest Recommendations

  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/19/2024Noble FinancialBoost TargetOutperform ➝ Outperform$6.00 ➝ $10.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
7/23/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
7/16/2024Roth CapitalUpgradeStrong-Buy
7/16/2024Roth MkmInitiated CoverageBuy$20.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/18/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $120.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
3/24/2023HC WainwrightReiterated RatingBuy$120.00
3/3/2023Dawson JamesInitiated CoverageBuy$60.00
2/15/2023HC WainwrightReiterated RatingBuy$120.00
2/1/2023HC WainwrightReiterated RatingBuy$120.00
11/15/2022Maxim GroupLower Target$45.00
10/26/2022HC WainwrightInitiated CoverageBuy$120.00
5/23/2022Maxim GroupReiterated RatingBuy$90.00
11/12/2021Maxim GroupInitiated CoverageBuy$150.00
5/7/2021Maxim GroupReiterated RatingBuy$120.00
11/19/2020Maxim GroupInitiated CoverageBuy$120.00
(Data available from 10/7/2019 forward)

News Sentiment Rating

-0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/10/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/8/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/7/2024
  • 1 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
9/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/6/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
GeoVax Labs logo
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Read More

Today's Range

Now: $2.07
Low: $2.00
High: $2.13

50 Day Range

MA: $3.48
Low: $1.76
High: $8.35

52 Week Range

Now: $2.07
Low: $1.09
High: $11.18

Volume

453,300 shs

Average Volume

2,504,812 shs

Market Capitalization

$4.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.05

Frequently Asked Questions

What sell-side analysts currently cover shares of GeoVax Labs?

The following equities research analysts have issued research reports on GeoVax Labs in the last year: EF Hutton Acquisition Co. I, HC Wainwright, Noble Financial, Roth Capital, and Roth Mkm.
View the latest analyst ratings for GOVX.

What is the current price target for GeoVax Labs?

3 Wall Street analysts have set twelve-month price targets for GeoVax Labs in the last year. Their average twelve-month price target is $12.67, suggesting a possible upside of 511.9%. Roth Mkm has the highest price target set, predicting GOVX will reach $20.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $8.00 for GeoVax Labs in the next year.
View the latest price targets for GOVX.

What is the current consensus analyst rating for GeoVax Labs?

GeoVax Labs currently has 3 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GOVX will outperform the market and that investors should add to their positions of GeoVax Labs.
View the latest ratings for GOVX.

What other companies compete with GeoVax Labs?

How do I contact GeoVax Labs' investor relations team?

GeoVax Labs' physical mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The company's listed phone number is (678) 384-7220 and its investor relations email address is [email protected]. The official website for GeoVax Labs is www.geovax.com. Learn More about contacing GeoVax Labs investor relations.